Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccine
Antitumor activity in human lymphocytes is triggered by vaccine
March 23rd, 2006
A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes. According to recent research from Germany, "We recently reported on newly designed virus-targeted bispecific CD3-and CD28-binding molecules for human T-cell activation. When bound via one arm to a human virus-modified tumor cell vaccine, these reagents caused a polyclonal T-cell response and overcame the potential various T-cell evasion mechanisms of tumor cells. In our current study, we demonstrated the induction of strong antitumor activity in human lymphocytes upon co-incubation with a virus-modified tumor vaccine containing...
Source: Women's Health Weekly (2006-03-23)
|
